Citalopram detailed information
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | 80% |
| Metabolism | hepatic (CYP3A4 & CYP2C19) |
| Elimination half-life | 35 hours |
| Excretion | Mostly as unmetabolized Citalopram, partly DCT and traces of DDCT in urine |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C20H21FN2O |
| Molar mass | 324.392 g/mol |
Citalopram is an antidepressant drug used to treat depression associated with mood disorders. It is also used on occasion in the treatment of body dysmorphic disorder and anxiety.
Citalopram belongs to a class of drugs known as selective serotonin reuptake inhibitors (SSRIs). It is sold under the brand-names Celexa™ (U.S., Forest Laboratories, Inc.), Cipramil™ , Citrol™, Seropram™ (Europe and Australia), Recital™ (Israel, Thrima Inc. for Unipharm Ltd.), Zetalo (India), Celepram™, Ciazil™ (Australia), Zentius™ (South America, Roemmers) and Cipram™ (Denmark, H. Lundbeck A/S).
History
Citalopram was originally created in 1989[1] by the pharmaceutical company Lundbeck. The patent expired in 2003, allowing other companies legally to produce generic versions.
Lundbeck has recently released an updated formulation called escitalopram (also known as Cipralex™ or Lexapro™), which is the S-enantiomer of the racemic citalopram (see below), and acquired a new patent for it. In the United States, Forest Laboratories licenses the rights for both Celexa and Lexapro from Lundbeck, which is based in Denmark.
Indications
Approved
Citalopram is primarily used to treat the symptoms of depression but can also be prescribed for social anxiety disorder, panic disorder or obsessive-compulsive disorder. Also prescribed in Huntington's disease and premenstrual dysphoric disorder.
Unapproved/Off-label/Investigational
Citalopram has been found to significantly reduce the symptoms of diabetic neuropathy[2] and premature ejaculation.[3] There is also evidence that citalopram may be effective in the treatment of post-stroke pathological crying.[4]
Dosage
Initially, 10 or 20mg once daily, in the morning or evening, with or without food. If response is inadequate, consider an increase to 40 mg/day in 20 mg increments at intervals of no less than 1 week. Some elderly patients may respond to 10 mg/day. Titrate to a maximum of 40 mg/day if needed and tolerated. Hepatic impairment: 30 mg/day (maximum dosage). If Celexa therapy is to be discontinued, taper the dose over 1-2 weeks.
Citalopram is formulated in 10, 20 and 40mg tablets.
Side effects and drug interactions
Citalopram is generally considered safe and well-tolerated in the therapeutic dose range of 20 to 60 mg/day. A doctor must always monitor a patient taking an SSRI like citalopram. Distinct from some other agents in its class, Citalopram exhibits linear pharmacokinetics and minimal drug interaction potential, making it a better choice for the elderly or comorbid patients.[5]
Citalopram can have a number of adverse effects. In clinical trials, over 10% of patients reported one or more of the following side effects: fatigue, drowsiness, dry mouth, increased sweating (hyperhidrosis), trembling, headache, dizziness, sleep disturbances, insomnia, cardiac arrythmia, blood pressure changes, nausea/vomiting, diarrhea, heightened anorgasmia in females, impotence and ejaculatory problems in males. In rare cases (around over 1% of cases), some allergic reactions, convulsions, mood changes, anxiety and confusion have been reported. Also sedation may be present during treatment of citalopram. If this occurs it is advisable to take the dose at bedtime instead of in the morning.
Another uncommon side effect is bruxism (teeth grinding).[6] When patients stop using Citalopram they may experience a feeling similar to electricity or minor shocks in their upper body and in their hands. This is caused by the chemical changes occurring in the brain and they pass with time. Occasionally, panic attacks, thoughts of suicide or self-harm may occur or increase in the first few weeks, before the antidepressant effect starts.[7]
Citalopram and other SSRIs have been shown to cause sexual side effects in some patients, both males and females.[8] Although usually reversible, these sexual side effects can sometimes last for months, years or possibly indefinitely even after the drug has been completely withdrawn. This disorder is known as Post SSRI Sexual Dysfunction.
Citalopram is contraindicated in individuals taking MAOIs. It is considered relatively safe in overdose, although fatal cases of dosages 840 mg to 1960 mg have been reported.[9]
Discontinuation or withdrawal syndrome has been reported with commencing of treatment. Tapering of Citalopram therapy, as opposed to abrupt discontinuation, is recommended in order to diminish the occurrence of discontinuation symptoms.
Stereochemistry
Citalopram has a stereocenter, to which a 4-fluorophenyl group and an N,N-dimethyl-3-aminopropyl group bind. Due to this chirality the molecule exists in (two) enantiomeric forms (mirror images). They are termed S-(+)-citalopram and R-(−)-citalopram.
-citalopram-3D-sticks.png) |
-citalopram-3D-sticks.png) |
-citalopram.png) |
-citalopram.png) |
| S-(+)-citalopram | R-(−)-citalopram |
Citalopram is sold as a racemic mixture, consisting of 50% R-(−)-citalopram and 50% S-(+)-citalopram. Only the S-(+) enantiomer has the desired antidepressant effect. Lundbeck now markets the S-(+) enantiomer, the generic name of which is escitalopram. Whereas citalopram is supplied as the hydrobromide, escitalopram is sold as the oxalate salt (hydrooxalate).[10] In both cases, the salt forms of the amine makes these otherwise lipophilic compounds water-soluble.
References
- ↑ Karin Dorell, M.D., Mary Ann Cohen, M.D., Shirish S. Huprikar, M.D., Jack M. Gorman, M.D., and Makeda Jones, M.D. (2005). "Citalopram-Induced Diplopia". Psychosomatics. 46 (1): 91–93.
- ↑ Sindrup SH, Bjerre U, Dejgaard A, Brosen K, Aaes-Jorgensen T, Gram LF. (1992). "The selective serotonin reuptake inhibitor citalopram relieves the symptoms of diabetic neuropathy". Clinical Pharmacology & Therapeutics. 52 (5): 547–552. PMID 1424428.
- ↑ Atmaca M, Kuloglu M, Tezcan E, Semercioz A. (2002). "The efficacy of citalopram in the treatment of premature ejaculation: a placebo-controlled study". International Journal of Impotence Research. 14 (6): 502–505. PMID 12494286.
- ↑ Andersen G., Vestergaard K., Riis JO. (1993). "Citalopram for post-stroke pathological crying". Lancet(British edition). 342 (8875): 837–839. PMID 8104273.
- ↑ http://www.biopsychiatry.com/citalopram.html
- ↑ "Bruxism/Teeth grinding". Mayo Clinic. 2007-05-18. Retrieved 2007-07-25.
- ↑ "Citalopram Hydrobromide Brand name: Celexa Drug monograph; Contraindications". Internet Mental Health. 1999. Retrieved 2007-07-25. Unknown parameter
|notes=ignored (help); Unknown parameter|month=ignored (help) - ↑ Clayton A, Keller A, McGarvey EL. Burden of phase-specific sexual dysfunction with SSRIs. J Affect Disord 2006;91:27-32. PMID 16430968.
- ↑ "Citalopram Hydrobromide Brand name: Celexa Drug monograph; Symptoms and Treatment of Overdosage". Internet Mental Health. 1999. Retrieved 2007-07-25. Unknown parameter
|notes=ignored (help); Unknown parameter|month=ignored (help)] - ↑ Celexa.com
External links
Pharmacological information and treatment study information:
Lunbeck's official websites for citalopram under the trade name Cipramil:
Forest's official websites for citalopram under the trade name Celexa:
- Celexa.com
- Celexa product page on Forest Laboratories web site
- Cipramil Patient Information Leaflet Cipramil Patient Information Leaflet
da:Citalopram de:Citalopram it:Citalopram hu:Citalopram nl:Citalopram no:Citalopram fi:Sitalopraami sv:Cipramil
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Pages with citations using unsupported parameters
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Selective serotonin reuptake inhibitors